A Phase IV, Real World Observational Study On The Use Of Akynzeo® (Netupitant/Palonosetron) For The Prevention Of Nausea and Vomiting in Oncology Patients Receiving Highly Emetogenic Chemotherapy (HEC) Over Multiple Cycles.

Status: Active, no longer recruiting

Phase of Trial: Phase IV

Latest Information Update: 07 Nov 2019

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Netupitant/palonosetron (Primary)
Indications Chemotherapy-induced nausea and vomiting
Focus Therapeutic Use
Acronyms EVOLVE_CINV
Sponsors Purdue Pharma

Most Recent Events

01 Nov 2019 Status changed from recruiting to active, no longer recruiting.
22 Oct 2018 Status changed from not yet recruiting to recruiting.
04 Sep 2018 New trial record

Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

Login with a username/password associated to an account with a valid subscription
Contact your organization’s admin about adding this content to your AdisInsight subscription
Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Welcome to AdisInsight